Table 2.
Baseline characteristics of patients with HCC in the NAFLD/NASH and other etiologies cohorts.
| Variables | NAFLD/NASH N = 110 (42%) |
Other etiologies N = 150 (58%) |
P-value |
|---|---|---|---|
| Gender, n (%) | .001 | ||
| Male | 70 (63.3) | 123 (82.0) | |
| Female | 40 (36.0) | 27 (18.0) | |
| Median age at surgery (years) | 66.7 | 63.4 | .005 |
| Race, n (%) | .001 | ||
| Caucasian | 69 (62.7) | 70 (46.6) | |
| Black | 0 (0) | 9 (6.0) | |
| Hispanic | 4(3.6) | 2 (1.3) | |
| Asian | 4 (3.6) | 34 (22.0) | |
| Other | 1 (0.9) | 0 (0) | |
| Unknown | 32 (29.0) | 35 (23.0) | |
| Risk factors, n (%) | |||
| HBV | 0 (0) | 41 (27.3) | |
| HCV | 0 (0) | 54 (36.0) | |
| HBV + HCV | 0 (0) | 6 (4) | |
| EtOH | 0 (0) | 43 (28.7) | |
| Hemochromatosis | 0 (0) | 5 (3.3) | |
| Other (alfa-1 antitrypsin deficiency) | 0 (0) | 1 (0.67) | |
| Cryptogenic | 49 (19) | 0 (0) | |
| MS | 60 (55.0) | 36 (24.0) | .001 |
| Diabetes | 51 (50.0) | 41 (25.0) | .001 |
| Hypertension | 84 (76.0) | 98 (65.3) | .037 |
| Hypercholesterolemia | 57 (51.8) | 44 (29.3) | .001 |
| Pre-surgical BMI ≥ 28.8 | 46 (43.4) | 37 (25.0) | .003 |
| Median pre-surgical labs | |||
| Total bilirubin | 0.5 | 0.6 | .14 |
| Albumin | 4.0 | 4.2 | .06 |
| Platelets | 252 | 175 | .0001 |
| INR | 1.1 | 1.1 | .58 |
| ALT | 34 | 45 | .004 |
| AST | 36 | 50 | .003 |
| AFP | 10.1 | 10.6 | .23 |
| Cr | 0.98 | 0.94 | .29 |
| MELD | 8.1 | 7.4 | .21 |
| Ascites, n (%) | 7 (6.3) | 8 (5.0) | .72 |
| Hepatic encephalopathy, n (%) | 0 (0) | 3 (2.0) | .13 |
Abbreviations: BMI, body mass index; HBV, chronic viral hepatitis B; HCC, hepatocellular carcinoma; HCV, chronic viral hepatitis C; MS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.